Advances in pharmacogenomics of cyclophosphamide in the breast cancer therapy

Abstract

Abstract: Cyclophosphamide (CPA) is widely used in the breast cancer therapy. However, significant individual differences of CPA in the pharmacokinetics, adverse reactions and efficacy have been observed, which made it difficult to decide a suitable dose in clinic. Previous clinical investigation indicated that functional genetic variation of metabolic enzymes of CPA played important roles in the metabolisms, adverse reactions and clinical efficacy of CPA. This paper reviews the recent clinical research advances about pharmacogenomics of CPA in the breast cancer therapy.

Key words: cyclophosphamide, breast cancer, pharmacogenomics, drug metabolized enzymes, chemotherapy

CLC Number:

R968
R969.1

HUANG Zheng-yu, LIU Fang-qun, GAO Li-chen, WANG Di, HE Yi-jing, CHENG Xiao-ping. Advances in pharmacogenomics of cyclophosphamide in the breast cancer therapy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(10): 1196-1200.

References 28

[1]	DeSantis C, Siegel R, Bandi P, et al. Breast cancer statistics[J]. CA Cancer J Clin, 2011, 61: 409-418.
[2]	Lyman GH, Dale DC, Tomita D, et al.A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting[J]. Breast Cancer Res Treat, 2013, 139(3): 863-872.
[3]	Pinto N, Ludeman SM, Dolan ME.Drug focus: pharmacogenetic studies related to cyclophosphamide-based therapy[J]. Pharmacogenomics, 2009, 10(12): 1893-1903.
[4]	Bray J, Sludden J, Griffin MJ, et al.Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide[J]. Br J Cancer, 2010, 102(6): 1003-1009.
[5]	Su HI, Sammel MD, Velders L, et al.Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors[J]. Fertil Steril, 2010, 94(2): 645-654.
[6]	Timm R, Kaiser R, Lotsch J, et al.Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19[J]. Pharmacogenomics J, 2005, 5(6): 365-373.
[7]	Wang D, Wang HB.Oxazaphosphorine bioactivation and detoxification: the role of xenobiotic receptors[J]. Acta Pharm Sin B, 2012, 2(2): 1-21.
[8]	Gor PP, Su HI, Gray RJ, et al.Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study[J]. Breast Cancer Res, 2010, 12(3): R26.
[9]	Huang Z, Roy P, Waxman DJ.Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide[J]. Biochem Pharmacol, 2000, 59(8): 961-972.
[10]	Roy P, Yu LJ, Crespi CL, et al.Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles[J]. Drug Metab Dispos, 1999, 27(6): 655-666.
[11]	Zhang H, Sridar C, Kenaan C, et al.Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex[J]. J Pharmacol Exp Ther, 2011, 338(3): 803-809.
[12]	Saitoh A, Sarles E, Capparelli E, et al.CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children[J]. AIDS, 2007, 21(16): 2191-2199.
[13]	Nyakutira C, Roshammar D, Chigutsa E, et al.High prevalence of the CYP2B6 516G.T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe[J]. Eur J Clin Pharmacol, 2008, 64(4): 357-365.
[14]	Zanger UM, Klein K.Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance[J]. Front Genet, 2013, 3(4): 1-12.
[15]	李莉华, 周希科, 何杰, 等. CYP2B6Q172H和K262R基因多态性对乳腺癌患者环磷酰胺化疗预后的影响[J]. 肿瘤防治研究, 2010, 37(12): 1387-1390.
[16]	陈江华, 赵建华, 唐金海, 等. 环磷酰胺代谢酶基因多态性与乳腺癌化疗反应相关性的探讨[J]. 中华肿瘤防治杂志, 2012, 19(10): 726-730.
[17]	王连生. 细胞色素P450氧化酶的遗传药理学[M]//周宏灏, 张伟主编. 遗传药理学. 2版. 北京:科学出版社, 2013: 110-111.
[18]	李清,郭栋. Ⅱ相药物代谢酶的遗传药理学[M]//周宏灏, 张伟主编. 遗传药理学. 2版. 北京:科学出版社, 2013: 146-150.
[19]	Ji MH, Tang JH, Zhao JH, et al.Polymorphisms in genes involved in drug detoxification and clinical outcomes of anthracycline-based neoadjuvant chemotherapy in Chinese Han breast cancer patients[J]. Cancer Bio Ther, 2012, 13(5): 264-271.
[20]	Yao S, Barlow WE, Albain KS, et al.Gene polymorphisms in cyclophosphamide metabolism pathway, treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer[J]. Clin Cancer Res, 2010, 16(24): 6169-6176.
[21]	Sweeney C, McClure Y, Fares MY, et al. Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism[J]. Clin Cancer Res, 2000, 60: 5621-5624.
[22]	Zhang BL, Sun T, Zhang BN, et al.Polymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancer[J]. Chin Med J, 2011,124(2): 199-204.
[23]	Yang G, Shu XO, Ruan ZX, et al.Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma[J]. Cancer, 2005, 103(1): 52-58.
[24]	Sweeney C, Ambrosone CB, Joseph LJ, et al.Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment[J]. Int J Cancer, 2003, 103(6): 810-814.
[25]	Ekhart C, Rodenhuis S, Smits PHM, et al.Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin[J]. Pharmacogenet Genomics, 2008, 18(11): 1009-1015.
[26]	Kim KP, Ahn JH, Kim SB, et al.Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy[J]. Cancer Chemother Pharmacol, 2012, 69(5): 1221-1227.
[27]	Low SK, Kiyotani K, Mushiroda T, et al.Association study of genetic polymorphism in ABCC4with cyclophosphamide-induced adverse drug reactions in breast cancer patients[J]. J Hum Genet, 2009, 54(10): 564-571.
[28]	孟祥光, 倪文琼, 王超, 等. 银屑病全身治疗的遗传药理学进展[J]. 中国临床药理学与治疗学, 2012, 17(11): 1307-1313.